Tests baricitinib for long-term safety in children with juvenile arthritis
Tests the drug baricitinib in children with juvenile idiopathic arthritis, aged 1 to 17.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Istanbul, TürkiyeSee the siteAlso in 19 other countries, 76 sites
- Trial code
- Registry title
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 190 people, planned
- Started
- 5 Apr 2019
- Expected to end
- Jul 2031
- Type of study
- Interventional
- Treatments tested
- Baricitinib
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teens with juvenile idiopathic arthritis who finished an earlier baricitinib study. It checks long-term safety and how well baricitinib works.
- Age
- From 1 year to under 18 years.
- Sex
- All sexes can join.
- Disease stage
- Juvenile idiopathic arthritis (JIA).
- Earlier treatment
- Must have completed a previous study of baricitinib for JIA.
Main reasons for not taking part
- Baricitinib was permanently stopped in the earlier study.
- Developed an allergy to baricitinib.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participants must have completed a previous study of baricitinib for the treatment of JIA
Who cannot take part
- Participants must not have had a permanent discontinuation of baricitinib in the prior study
- Participants must have not developed an allergy to baricitinib
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Where in Türkiye
Also in 19 other countries, 76 sites
- Istanbul University Cerrahpaşa - Cerrahpaşa Faculty of MedicineIstanbul, TürkiyeContact: Ozgur Kasapcopur (principal investigator)Taking people
About the trial
What the trial wants to find out
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
The group in the trial
- BaricitinibTreatment being tested
Baricitinib given orally.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
- Plain-language title
- Tests baricitinib for long-term safety in children with juvenile arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03773965, who can take part
- Record updated
- 4 November 2026